merck moderna - Search News

Moderna, Merck and melanoma

Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

Pharmaceutical giants Moderna and Merck said Wednesday that an experimental vaccine treatment has shown signs of preventing cancer from returning or spreading in a study of high-risk melanoma patients...

· 5h

Moderna, Merck mRNA Cancer Vaccine Cuts Recurrence And Spread Of Melanoma

· 8h

Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors.

· 10h

Moderna and Merck Say mRNA Vaccine Prevents Melanoma From Returning

The companies say the vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

The Economist · 11h

World in Brief: Skin-cancer vaccine shows promise; Treasury props up bonds

· 8h

VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results

· 12h

Moderna-Merck melanoma therapy averts cancer recurrence in study

The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone.

· 1h

Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock soared.

· 13h

Cancer vaccine using mRNA succeeded in late-stage melanoma trial, Moderna and Merck say

Moderna and Merck Revive mRNA Hopes With Melanoma Success

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology.

24/7 Wall St.

Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rocketing higher Wednesday morning, with the stock up 93% to $121.76 in early Wednesday trading after the company and partner Merck (NYSE:MRK) announced that their Phase 3 melanoma trial met its primary endpoint.

14h

Moderna, Merck, SK Hynix, Micron, Target, Estée Lauder, and More Stocks That Explain Today’s Market

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

17h

Why is Moderna stock up 87% today during premarket trade?

The late-stage melanoma trial with Merck’s Keytruda shows both lower recurrence and less spread, with no new safety signals—this is the clearest proof yet that Moderna’s personalized mRNA can work as an add-on to a major checkpoint therapy.